Detailed description page of THPdb

This page displays user query in tabular form.

Th1183 details

Primary information
ID 1757
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name NA
Company NA
Brand Discription NA
Prescribed for NA
Chemical Name NA
Formulation 220 [iU]/mL, 1560 [iU]/5mL, 312 [iU]/mL - Injections; 312 [iU]/mL, 50 mg/mL - Injections solutions
Physcial Appearance Injection; Solution
Route of Administration Intra muscular; IV
Recommended Dosage NA
Contraindication NA
Side Effects NA
Useful Link
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1758
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Hepagam B
Company Cangene Bio Pharma Inc.
Brand Discription HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name NA
Formulation 50 mg/mL
Physcial Appearance injection, solution
Route of Administration intramuscular; intravenous
Recommended Dosage Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1759
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Hepagam B
Company Cangene Bio Pharma Inc.
Brand Discription HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name NA
Formulation 50 mg/mL
Physcial Appearance injection, solution
Route of Administration intramuscular; intravenous
Recommended Dosage Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1760
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Hepagam B
Company Cangene Bio Pharma Inc.
Brand Discription HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name NA
Formulation 312 [iU]/mL
Physcial Appearance injection, solution
Route of Administration intramuscular; intravenous
Recommended Dosage Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1761
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Hepagam B
Company Cangene Bio Pharma Inc.
Brand Discription HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name NA
Formulation 312 [iU]/mL
Physcial Appearance injection, solution
Route of Administration intramuscular; intravenous
Recommended Dosage Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1762
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Hyperhep B S/d
Company GRIFOLS USA, LLC
Brand Discription HyperHEP BÂ® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of hepatitis B hyperimmune immune globulin for intramuscular administration; it is preservative-free and latex-free. HyperHEP B S/D is prepared by cold ethanol fractionation from the plasma of donors with high titers of antibody to the hepatitis B surface antigen (anti-HBs). The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solution is adjusted to a final concentration of 0.3% tri-n-butyl phosphate (TNBP) and 0.2% sodium cholate. After the addition of solvent (TNBP) and detergent (sodium cholate), the solution is heated to 30Â°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. HyperHEP B S/D is formulated as a 15â€“18% protein solution at a pH of 6.4â€“7.2 in 0.21â€“0.32 M glycine. HyperHEP B S/D is then incubated in the final container for 21â€“28 days at 20â€“27Â°C.
Prescribed for Recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future HBV exposure for the person requiring treatment. In all exposures, a regimen combining Hepatitis B Immune Globulin (Human) with hepatitis B vaccine will provide both short- and long-term protection, will be less costly than the two-dose Hepatitis B Immune Globulin (Human) treatment alone, and is the treatment of choice. Also for post-exposure prophyllaxis for Acute Exposure To Blood Containing HBsAg, Perinatal Exposure Of Infants Born To HBsAg-positive Mothers, Sexual Exposure To An HBsAg-positive Person and Household Exposure To Persons With Acute HBV Infection.
Chemical Name NA
Formulation 220 [iU]/mL
Physcial Appearance Injection
Route of Administration Intramuscular
Recommended Dosage For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication NA
Side Effects Local pain and tenderness at the injection site, urticaria and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immune globulin preparations.
Useful Link http://www.rxlist.com/hyperhep-b-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1763
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Nabi-HB
Company Biotest Pharmaceuticals Corporation
Brand Discription Nabi-HB (hepatitis b vaccine recombinant) , is a sterile solution of immunoglobulin (5 Â± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs.
Prescribed for Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute Exposure to Blood Containing HBsAg; Perinatal Exposure of Infants Born to HBsAg-positive Mothers; Sexual Exposure to HBsAg-positive Persons; Household Exposure to Persons with Acute HBV Infection.
Chemical Name NA
Formulation 1560 [iU]/5mL
Physcial Appearance Injection
Route of Administration Intramuscular
Recommended Dosage For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication ndividuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB, Hepatitis B Immune Globulin (Human), or any other human immune globulin. Nabi-HB (hepatitis b vaccine recombinant) contains less than 100 micrograms per mL IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylac-toid reaction. The physician must weigh the potential benefit of treatment with Nabi-HB (hepatitis b vaccine recombinant) against the potential for hypersensitivity reactions
Side Effects The number of patients with reactions related to the administration of Nabi-HB (hepatitis b vaccine recombinant) included local reactions such as erythema 6 (12%) and ache 2 (4%) at the injection site, as well as systemic reactions such as headache 7 (14%), myal-gia 5 (10%), malaise 3 (6%), nausea 2 (4%), and vomiting 1 (2%). The majority (92%) of reactions were reported as mild. The following adverse events were reported in the phar-macokinetics trials and were considered probably related to Nabi-HB (hepatitis b vaccine recombinant) : elevated alkaline phos-phatase 2 (4%), ecchymosis 1 (2%), joint stiffness 1 (2%), elevated AST 1 (2%), decreased WBC 1 (2%), and elevated creatinine 1 (2%). All adverse events were mild in intensity. There were no serious adverse events. No anaphylactic reactions with Nabi-HB (hepatitis b vaccine recombinant) have been reported. However, these reactions, although rare, have been reported following the injection of human immune globulins
Useful Link http://www.rxlist.com/nabi-hb-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

Primary information
ID 1764
ThPP ID Th1183
Therapeutic Peptide/Protein Name Hepatitis B immune globulin
Sequence NA view full sequnce in fasta
Functional Classification IIIa
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life 22-25 days
Description Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics NA
Mechanism of Action In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution approximately 7.5 L
Clearance The mean clearance rate was 0.21 to 0.24 L/day
Categories NA
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction NA
Target HBsAg
Information of corresponding available drug in the market
Brand Name Nabi-HB
Company Biotest Pharmaceuticals Corporation
Brand Discription Nabi-HB (hepatitis b vaccine recombinant) , is a sterile solution of immunoglobulin (5 Â± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs.
Prescribed for Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute Exposure to Blood Containing HBsAg; Perinatal Exposure of Infants Born to HBsAg-positive Mothers; Sexual Exposure to HBsAg-positive Persons; Household Exposure to Persons with Acute HBV Infection.
Chemical Name NA
Formulation 312 [iU]/mL
Physcial Appearance Injection
Route of Administration Intramuscular
Recommended Dosage For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication ndividuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB, Hepatitis B Immune Globulin (Human), or any other human immune globulin. Nabi-HB (hepatitis b vaccine recombinant) contains less than 100 micrograms per mL IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylac-toid reaction. The physician must weigh the potential benefit of treatment with Nabi-HB (hepatitis b vaccine recombinant) against the potential for hypersensitivity reactions
Side Effects The number of patients with reactions related to the administration of Nabi-HB (hepatitis b vaccine recombinant) included local reactions such as erythema 6 (12%) and ache 2 (4%) at the injection site, as well as systemic reactions such as headache 7 (14%), myal-gia 5 (10%), malaise 3 (6%), nausea 2 (4%), and vomiting 1 (2%). The majority (92%) of reactions were reported as mild. The following adverse events were reported in the phar-macokinetics trials and were considered probably related to Nabi-HB (hepatitis b vaccine recombinant) : elevated alkaline phos-phatase 2 (4%), ecchymosis 1 (2%), joint stiffness 1 (2%), elevated AST 1 (2%), decreased WBC 1 (2%), and elevated creatinine 1 (2%). All adverse events were mild in intensity. There were no serious adverse events. No anaphylactic reactions with Nabi-HB (hepatitis b vaccine recombinant) have been reported. However, these reactions, although rare, have been reported following the injection of human immune globulins
Useful Link http://www.rxlist.com/nabi-hb-drug/side-effects-interactions.htm
PubMed ID 23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1757
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	NA
Company	NA
Brand Discription	NA
Prescribed for	NA
Chemical Name	NA
Formulation	220 [iU]/mL, 1560 [iU]/5mL, 312 [iU]/mL - Injections; 312 [iU]/mL, 50 mg/mL - Injections solutions
Physcial Appearance	Injection; Solution
Route of Administration	Intra muscular; IV
Recommended Dosage	NA
Contraindication	NA
Side Effects	NA
Useful Link
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1758
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Hepagam B
Company	Cangene Bio Pharma Inc.
Brand Discription	HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for	HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name	NA
Formulation	50 mg/mL
Physcial Appearance	injection, solution
Route of Administration	intramuscular; intravenous
Recommended Dosage	Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication	Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects	The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link	http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1759
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Hepagam B
Company	Cangene Bio Pharma Inc.
Brand Discription	HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for	HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name	NA
Formulation	50 mg/mL
Physcial Appearance	injection, solution
Route of Administration	intramuscular; intravenous
Recommended Dosage	Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication	Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects	The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link	http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1760
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Hepagam B
Company	Cangene Bio Pharma Inc.
Brand Discription	HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for	HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name	NA
Formulation	312 [iU]/mL
Physcial Appearance	injection, solution
Route of Administration	intramuscular; intravenous
Recommended Dosage	Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication	Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects	The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link	http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1761
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Hepagam B
Company	Cangene Bio Pharma Inc.
Brand Discription	HepaGam B, Hepatitis B Immune Globulin Intravenous (Human), is a solvent/detergent- treated sterile solution of purified gamma globulin containing anti-HBs. It is prepared from plasma donated by healthy, screened donors with high titers of anti-HBs that is purified by an anion- exchange column chromatography manufacturing method9,10. HepaGam B (hepatitis b immune globulin human) is formulated as a 5% (50 mg/mL) protein solution with 10% maltose and 0.03% polysorbate 80 at pH 5.6. It is available in 1 mL and 5 mL single dose vials. The product appears as a clear to opalescent liquid.
Prescribed for	HepaGam Bâ„¢, Hepatitis B Immune Globulin Intravenous (Human), is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg-positive liver transplant patients.
Chemical Name	NA
Formulation	312 [iU]/mL
Physcial Appearance	injection, solution
Route of Administration	intramuscular; intravenous
Recommended Dosage	Based upon the HepaGam B (hepatitis b immune globulin (human)) clinical trial, patients should receive 20,000 lU/dose [see Clinical Trials in Liver Transplant Patients]. The volume of each 20,000 IU dose should be calculated from the measured potency of the particular lot of HepaGam Bâ„¢ (Hepatitis B Immune Globulin Intravenous [Human]) as stamped on the vial label. The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended
Contraindication	Individuals known to have anaphylactic or severe systematic reactions associated with the parenteral administration of human globulin preparations should not receive HepaGam B (hepatitis b immune globulin (human)) , (Hepatitis B Immune Globulin Intravenous [Human]), or any other human immune globulin. HepaGam B (hepatitis b immune globulin (human)) contains less than 40 micro-grams/mL of IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction. The physician must weigh the potential benefit of treatment with HepaGam B (hepatitis b immune globulin (human)) against the potential for hypersensitivity reactions. For postexposure prophylaxis indications, HepaGam B (hepatitis b immune globulin (human)) must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B (hepatitis b immune globulin (human)) should be given only if the expected benefits outweigh the potential risks.
Side Effects	The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B (hepatitis b immune globulin (human)) are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Useful Link	http://www.rxlist.com/hepagam-b-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1762
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Hyperhep B S/d
Company	GRIFOLS USA, LLC
Brand Discription	HyperHEP BÂ® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of hepatitis B hyperimmune immune globulin for intramuscular administration; it is preservative-free and latex-free. HyperHEP B S/D is prepared by cold ethanol fractionation from the plasma of donors with high titers of antibody to the hepatitis B surface antigen (anti-HBs). The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solution is adjusted to a final concentration of 0.3% tri-n-butyl phosphate (TNBP) and 0.2% sodium cholate. After the addition of solvent (TNBP) and detergent (sodium cholate), the solution is heated to 30Â°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. HyperHEP B S/D is formulated as a 15â€“18% protein solution at a pH of 6.4â€“7.2 in 0.21â€“0.32 M glycine. HyperHEP B S/D is then incubated in the final container for 21â€“28 days at 20â€“27Â°C.
Prescribed for	Recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future HBV exposure for the person requiring treatment. In all exposures, a regimen combining Hepatitis B Immune Globulin (Human) with hepatitis B vaccine will provide both short- and long-term protection, will be less costly than the two-dose Hepatitis B Immune Globulin (Human) treatment alone, and is the treatment of choice. Also for post-exposure prophyllaxis for Acute Exposure To Blood Containing HBsAg, Perinatal Exposure Of Infants Born To HBsAg-positive Mothers, Sexual Exposure To An HBsAg-positive Person and Household Exposure To Persons With Acute HBV Infection.
Chemical Name	NA
Formulation	220 [iU]/mL
Physcial Appearance	Injection
Route of Administration	Intramuscular
Recommended Dosage	For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication	NA
Side Effects	Local pain and tenderness at the injection site, urticaria and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immune globulin preparations.
Useful Link	http://www.rxlist.com/hyperhep-b-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1763
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Nabi-HB
Company	Biotest Pharmaceuticals Corporation
Brand Discription	Nabi-HB (hepatitis b vaccine recombinant) , is a sterile solution of immunoglobulin (5 Â± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs.
Prescribed for	Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute Exposure to Blood Containing HBsAg; Perinatal Exposure of Infants Born to HBsAg-positive Mothers; Sexual Exposure to HBsAg-positive Persons; Household Exposure to Persons with Acute HBV Infection.
Chemical Name	NA
Formulation	1560 [iU]/5mL
Physcial Appearance	Injection
Route of Administration	Intramuscular
Recommended Dosage	For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication	ndividuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB, Hepatitis B Immune Globulin (Human), or any other human immune globulin. Nabi-HB (hepatitis b vaccine recombinant) contains less than 100 micrograms per mL IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylac-toid reaction. The physician must weigh the potential benefit of treatment with Nabi-HB (hepatitis b vaccine recombinant) against the potential for hypersensitivity reactions
Side Effects	The number of patients with reactions related to the administration of Nabi-HB (hepatitis b vaccine recombinant) included local reactions such as erythema 6 (12%) and ache 2 (4%) at the injection site, as well as systemic reactions such as headache 7 (14%), myal-gia 5 (10%), malaise 3 (6%), nausea 2 (4%), and vomiting 1 (2%). The majority (92%) of reactions were reported as mild. The following adverse events were reported in the phar-macokinetics trials and were considered probably related to Nabi-HB (hepatitis b vaccine recombinant) : elevated alkaline phos-phatase 2 (4%), ecchymosis 1 (2%), joint stiffness 1 (2%), elevated AST 1 (2%), decreased WBC 1 (2%), and elevated creatinine 1 (2%). All adverse events were mild in intensity. There were no serious adverse events. No anaphylactic reactions with Nabi-HB (hepatitis b vaccine recombinant) have been reported. However, these reactions, although rare, have been reported following the injection of human immune globulins
Useful Link	http://www.rxlist.com/nabi-hb-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Primary information
ID	1764
ThPP ID	Th1183
Therapeutic Peptide/Protein Name	Hepatitis B immune globulin
Sequence	NA view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	22-25 days
Description	Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication/Disease	Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Pharmacodynamics	NA
Mechanism of Action	In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	approximately 7.5 L
Clearance	The mean clearance rate was 0.21 to 0.24 L/day
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	NA
Target	HBsAg
Information of corresponding available drug in the market
Brand Name	Nabi-HB
Company	Biotest Pharmaceuticals Corporation
Brand Discription	Nabi-HB (hepatitis b vaccine recombinant) , is a sterile solution of immunoglobulin (5 Â± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs.
Prescribed for	Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute Exposure to Blood Containing HBsAg; Perinatal Exposure of Infants Born to HBsAg-positive Mothers; Sexual Exposure to HBsAg-positive Persons; Household Exposure to Persons with Acute HBV Infection.
Chemical Name	NA
Formulation	312 [iU]/mL
Physcial Appearance	Injection
Route of Administration	Intramuscular
Recommended Dosage	For Acute Exposure To Blood Containing HBsAg: For greatest effectiveness, passive prophylaxis with Hepatitis B Immune Globulin (Human) should be given as soon as possible after exposure (its value beyond 7 days of exposure is unclear). If Hepatitis B Immune Globulin (Human) is indicated, an injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours, if possible. Consult Hepatitis B Vaccine package insert for dosage information regarding that product; for Prophylaxis Of Infants Born To HBsAg And HBeAg Positive Mothers: Efficacy of prophylactic Hepatitis B Immune Globulin (Human) in infants at risk depends on administering Hepatitis B Immune Globulin (Human) on the day of birth. It is therefore vital that HBsAg-positive mothers be identified before delivery; For Sexual Exposure To An HBsAg-positive Person: All susceptible persons whose sex partners have acute hepatitis B infection should receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine series if prophylaxis can be started within 14 days of the last sexual contact or if sexual contact with the infected person will continue (see Table 2 below). Administering the vaccine with HBIG may improve the efficacy of postexposure treatment. The vaccine has the added advantage of conferring long-lasting protection; For Household Exposure To Persons With Acute HBV Infection: Prophylactic treatment with a 0.5 mL dose of Hepatitis B Immune Globulin (Human) and hepatitis B vaccine is indicated for infants 12 months of age who have been exposed to a primary care-giver who has acute hepatitis B. Prophylaxis for other household contacts of persons with acute HBV infection is not indicated unless they have had identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
Contraindication	ndividuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB, Hepatitis B Immune Globulin (Human), or any other human immune globulin. Nabi-HB (hepatitis b vaccine recombinant) contains less than 100 micrograms per mL IgA. Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylac-toid reaction. The physician must weigh the potential benefit of treatment with Nabi-HB (hepatitis b vaccine recombinant) against the potential for hypersensitivity reactions
Side Effects	The number of patients with reactions related to the administration of Nabi-HB (hepatitis b vaccine recombinant) included local reactions such as erythema 6 (12%) and ache 2 (4%) at the injection site, as well as systemic reactions such as headache 7 (14%), myal-gia 5 (10%), malaise 3 (6%), nausea 2 (4%), and vomiting 1 (2%). The majority (92%) of reactions were reported as mild. The following adverse events were reported in the phar-macokinetics trials and were considered probably related to Nabi-HB (hepatitis b vaccine recombinant) : elevated alkaline phos-phatase 2 (4%), ecchymosis 1 (2%), joint stiffness 1 (2%), elevated AST 1 (2%), decreased WBC 1 (2%), and elevated creatinine 1 (2%). All adverse events were mild in intensity. There were no serious adverse events. No anaphylactic reactions with Nabi-HB (hepatitis b vaccine recombinant) have been reported. However, these reactions, although rare, have been reported following the injection of human immune globulins
Useful Link	http://www.rxlist.com/nabi-hb-drug/side-effects-interactions.htm
PubMed ID	23239274, 28209492, 28199772, 27439498, 27422771, 27298109, 27255707, 26859222, 26713590
3-D Structure	N.A.

Updated version of this database is available at ThpDB2

Detailed description page of THPdb